The drug-development standard that a pill is always better than a shot may not pull as much weight when it comes to treating allergies, and this could be true even when multiple injections are involved.
Briefing papers for the meeting next week of the FDA’s Allergenic Products Advisory Committee suggest that the panel will green-light the sublingual ragweed allergy therapy from Alk-Abello A/S and Merck and Co. Inc., just as the grass-pollen allergy tablet sailed through last month.
Squaring off against anemia leader Amgen Inc., with help from high-powered partner Celgene Corp., Acceleron Pharma Inc. expects to raise $120 million through the sale of 2.4 million shares at $50 each.
The delayed PDUFA date and lack of labeling talks with the FDA presaged unhappy news for Amag Pharmaceuticals Inc. regarding its supplemental new drug application (sNDA) for intravenous Feraheme (ferumoxytol), and a complete response letter (CRL) came next.
“Disappointed but not surprised” by the FDA’s refusal to go back on its surprise withdrawal of the special protocol assessment (SPA) deal for the trial known as ANCHOR, Amarin Corp. plc is moving to the next step in seeking a broader label on the triglyceride-lowering therapy Vascepa (icosapent ethyl), said CEO John Thero.
Emotional intelligence. The importance of face-to-face meetings. How to craft a deal by making friends first, and finding common ground. Such are often the topics of talk when the J.P. Morgan Healthcare Conference (JPM) comes up.
SAN FRANCISCO – On the first morning of the 32nd Annual J.P. Morgan (JPM) Healthcare Conference, Carol Gallagher, unlike almost everyone else in JPM’s orbit, seemed calm, quiet and reflective.
SAN FRANCISCO – “Two or three years ago you would see sad faces walking around the halls of the Westin St. Francis,” said Ram May-Ron, managing partner with the Freemind Group. “Today, it’s slightly better.”
SAN FRANCISCO – As California’s year-long drought continued, Regeneron Pharmaceuticals Inc. refreshed investors at the 32nd Annual J.P. Morgan Healthcare Conference (JPM) with news of a new deal for a combination therapy in wet age-related macular degeneration (AMD).
SAN FRANCISCO – As Wall Street calmed in the wake of Alnylam Pharmaceuticals Inc.’s double shot of news – a $700 million expansion of the pact with Sanofi SA’s Genzyme unit, and the $175 million buyout of RNAi peer Sirna Therapeutics Inc. – investor eyes turned to the prospects of ALN-TTR-sc, the subcutaneous therapy targeting transthyretin (TTR), in Phase II trials for familial amyloid cardiomyopathy (FAC).
